JP2002540767A - エポキシドヒドロラーゼ複合体とそれを用いた方法 - Google Patents

エポキシドヒドロラーゼ複合体とそれを用いた方法

Info

Publication number
JP2002540767A
JP2002540767A JP2000599385A JP2000599385A JP2002540767A JP 2002540767 A JP2002540767 A JP 2002540767A JP 2000599385 A JP2000599385 A JP 2000599385A JP 2000599385 A JP2000599385 A JP 2000599385A JP 2002540767 A JP2002540767 A JP 2002540767A
Authority
JP
Japan
Prior art keywords
compound
epoxide hydrolase
sulfur
epoxide
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000599385A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002540767A5 (enExample
Inventor
ブルース、 ディー． ハモック、
クリストフ、 エイチ． モリソー、
ジアン ジォン、
マーヴィン、 エイチ． グッドロウ、
トーニャ セヴァーソン、
ジェームズ サンボーン、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JP2002540767A publication Critical patent/JP2002540767A/ja
Publication of JP2002540767A5 publication Critical patent/JP2002540767A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2000599385A 1999-02-18 2000-02-10 エポキシドヒドロラーゼ複合体とそれを用いた方法 Pending JP2002540767A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/252,148 1999-02-18
US09/252,148 US6150415A (en) 1996-08-13 1999-02-18 Epoxide hydrolase complexes and methods therewith
PCT/US2000/003495 WO2000048593A1 (en) 1999-02-18 2000-02-10 Epoxide hydrolase complexes and methods therewith

Publications (2)

Publication Number Publication Date
JP2002540767A true JP2002540767A (ja) 2002-12-03
JP2002540767A5 JP2002540767A5 (enExample) 2007-03-29

Family

ID=22954799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000599385A Pending JP2002540767A (ja) 1999-02-18 2000-02-10 エポキシドヒドロラーゼ複合体とそれを用いた方法

Country Status (10)

Country Link
US (1) US6150415A (enExample)
EP (2) EP1844767B1 (enExample)
JP (1) JP2002540767A (enExample)
AT (1) ATE375153T1 (enExample)
AU (1) AU3360800A (enExample)
CA (1) CA2362331C (enExample)
DE (1) DE60036690T2 (enExample)
DK (1) DK1154764T3 (enExample)
ES (1) ES2291196T3 (enExample)
WO (1) WO2000048593A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008517072A (ja) * 2004-10-20 2008-05-22 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア 可溶性エポキシド加水分解酵素の改良された阻害剤

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150415A (en) * 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US8815951B2 (en) * 1996-08-13 2014-08-26 The Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of inflammation
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) * 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US6831099B1 (en) * 1999-05-12 2004-12-14 Yale University Enzyme inhibition
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6562563B1 (en) * 1999-11-03 2003-05-13 Mitokor Compositions and mehtods for determining interactions of mitochondrial components, and for identifying agents that alter such interactions
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2002082082A2 (en) * 2001-04-09 2002-10-17 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorescence polarization assay
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US6756210B2 (en) * 2001-05-29 2004-06-29 The Regents Of The University Of California Linoleic acid diol and glucuronide conjugate levels as diagnostic markers of disorders of abnormal regulation of cytochrome P450 metabolism of unsaturated fatty acids
CA2456229A1 (en) * 2001-08-03 2003-02-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
US6943001B2 (en) * 2001-08-03 2005-09-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
US20030139469A1 (en) * 2002-01-23 2003-07-24 The Regents Of The University Of California Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation
ATE529406T1 (de) 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
GB0214342D0 (en) * 2002-06-21 2002-07-31 Givaudan Sa Insect repellents
EP1558591B1 (en) 2002-10-07 2014-05-07 The Regents of The University of California Modulation of anxiety through blockade of anandamide hydrolysis
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
WO2004089296A2 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
US20050164951A1 (en) * 2003-04-03 2005-07-28 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
EP1765311A4 (en) * 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
WO2006121684A2 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International, Gmbh Acyl hydrazones for treating cardiovascular diseases
US20060276515A1 (en) * 2005-05-06 2006-12-07 Cywin Charles L Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same
CA2619768A1 (en) * 2005-08-19 2007-02-22 The Regents Of The University Of California Use of seh inhibitors as analgesics
WO2007044491A1 (en) * 2005-10-07 2007-04-19 Boehringer Ingelheim International Gmbh N-substituted pyridinone or pyrimidinone compounds useful as soluble epoxide hydrolase inhibitors
EP2623113B1 (en) 2005-11-09 2017-05-31 Onyx Therapeutics, Inc. Compound for enzyme inhibition
CA2636601C (en) * 2006-01-13 2019-03-19 Cosmas Therapeutics Development Inc. Novel melatonin ligands having antidepressant activity as well as sleep inducing properties
WO2007106705A1 (en) * 2006-03-10 2007-09-20 Boehringer Ingelheim International Gmbh Soluble epoxide hydrolase inhibitors and methods of using same
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
EP2124928A4 (en) * 2006-12-15 2011-01-05 Univ California USE OF CIS EPOXY EICOSATRIC ACIDS AND INHIBITORS OF SOLUBLE EPOXY HYDROLASE FOR THE TREATMENT OF DISEASES CAUSED BY PBR, CB2 AND NK
EP2091542A1 (en) * 2006-12-18 2009-08-26 F. Hoffmann-Roche AG Novel use of inhibitors of soluble epoxide hydrolase
WO2009011872A1 (en) * 2007-07-17 2009-01-22 Merck & Co., Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
WO2009020960A1 (en) 2007-08-06 2009-02-12 The Regents Of The University Of California Preparation of novel 1,3-substituted ureas as inhibitors of soluble epoxide hydrolase
CA2701778C (en) 2007-10-04 2018-09-11 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
WO2009111207A1 (en) * 2008-03-04 2009-09-11 Merck & Co., Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンを用いた併用療法
WO2010096722A1 (en) 2009-02-20 2010-08-26 Takeda Pharmaceutical Company Limited 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
CA2795559A1 (en) 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
EP2389922A1 (en) 2010-05-25 2011-11-30 Symrise AG Cyclohexyl carbamate compounds as anti-ageing actives
US9029401B2 (en) 2011-02-14 2015-05-12 The Regents Of The University Of California Sorafenib derivatives as sEH inhibitors
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US9034903B2 (en) 2012-02-01 2015-05-19 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
WO2013138118A1 (en) 2012-03-14 2013-09-19 The Regents Of The University Of California Treatment of inflammatory disorders in non-human mammals
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
US10813894B2 (en) 2015-02-20 2020-10-27 The Regents Of The University Of California Methods of inhibiting pain
EP3463470A1 (en) 2016-05-25 2019-04-10 Johann Wolfgang Goethe-Universität Frankfurt am Main Treatment and diagnosis of non-proliferative diabetic retinopathy
US20210378995A1 (en) 2018-10-10 2021-12-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and topical pharmaceutical compositions for the treatment of skin microvascular dysfunction
CA3118924A1 (en) 2018-11-09 2020-05-14 Ginkgo Bioworks, Inc. Biosynthesis of mogrosides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03215420A (ja) * 1989-06-08 1991-09-20 Procter & Gamble Co:The 呼吸疾患又は障害の治療に関するバニロイド類の用途
JPH04270255A (ja) * 1990-02-26 1992-09-25 Merrell Dow Pharmaceut Inc 酸化窒素生合成の抑制剤
JPH08301840A (ja) * 1995-03-07 1996-11-19 Santen Pharmaceut Co Ltd Ｎ，ｎ−ジアルキルアミノフェニル基を有する新規アミノ酸誘導体
WO1998006261A1 (en) * 1996-08-13 1998-02-19 The Regents Of The University Of California Methods of treating pulmonary diseases mediated by polyunsaturated lipid metabolites and assays for epoxide hydrolase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1056290A (en) * 1963-05-06 1967-01-25 Du Pont Dicycloalkyl ureas
US5445956A (en) * 1993-08-13 1995-08-29 The Regents Of The University Of California Recombinant soluble epoxide hydrolase
US5599984A (en) * 1994-01-21 1997-02-04 The Picower Institute For Medical Research Guanylhydrazones and their use to treat inflammatory conditions
US6150415A (en) * 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03215420A (ja) * 1989-06-08 1991-09-20 Procter & Gamble Co:The 呼吸疾患又は障害の治療に関するバニロイド類の用途
JPH04270255A (ja) * 1990-02-26 1992-09-25 Merrell Dow Pharmaceut Inc 酸化窒素生合成の抑制剤
JPH08301840A (ja) * 1995-03-07 1996-11-19 Santen Pharmaceut Co Ltd Ｎ，ｎ−ジアルキルアミノフェニル基を有する新規アミノ酸誘導体
WO1998006261A1 (en) * 1996-08-13 1998-02-19 The Regents Of The University Of California Methods of treating pulmonary diseases mediated by polyunsaturated lipid metabolites and assays for epoxide hydrolase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008517072A (ja) * 2004-10-20 2008-05-22 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア 可溶性エポキシド加水分解酵素の改良された阻害剤

Also Published As

Publication number Publication date
US6150415A (en) 2000-11-21
DE60036690T2 (de) 2008-07-17
ES2291196T3 (es) 2008-03-01
WO2000048593A1 (en) 2000-08-24
DE60036690D1 (de) 2007-11-22
EP1154764B1 (en) 2007-10-10
EP1154764A4 (en) 2005-02-16
CA2362331C (en) 2010-04-20
EP1844767A3 (en) 2010-01-13
EP1844767B1 (en) 2012-08-29
EP1844767A2 (en) 2007-10-17
AU3360800A (en) 2000-09-04
EP1154764A1 (en) 2001-11-21
DK1154764T3 (da) 2008-02-04
ATE375153T1 (de) 2007-10-15
CA2362331A1 (en) 2000-08-24

Similar Documents

Publication Publication Date Title
US6150415A (en) Epoxide hydrolase complexes and methods therewith
US20060035869A1 (en) Inhibitors of epoxide hydrolases for the treatment of hypertension
Underwood et al. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram.
Vandiver et al. Hydrogen sulfide: a gasotransmitter of clinical relevance
Nagatsu Progress in monoamine oxidase (MAO) research in relation to genetic engineering
Baxter et al. Elevation of γ-aminobutyric acid in brain: selective inhibition of γ-aminobutyric-α-ketoglutaric acid transaminase
Moncada et al. The discovery of nitric oxide as the endogenous nitrovasodilator.
Han et al. The in vivo gene expression signature of oxidative stress
Klaas et al. Studies on the anti-inflammatory activity of phytopharmaceuticals prepared from Arnica flowers
Graf et al. Acidic nonsteroid anti-inflammatory drugs accumulating in inflamed tissue
US20030149082A1 (en) Inhibitors of the anandamide transporter as analgesic agents
McMillan Leukotrienes in respiratory disease
Hospattankar et al. Changes in liver lipids after administration of 2-decanoylamino-3-morpholinopropiophenone and chlorpromazine
JPH07502730A (ja) 医薬組成物及び該組成物の調製方法
Avner et al. Desensitization of isolated human bronchial smooth muscle to β-receptor agonists
DuBois et al. Quantitative measurement of inhibition of aliesterases, acylamidase, and cholinesterase by EPN and Delnav®
Hwang et al. Isodihydrocapsiate stimulates plasma glucose uptake by activation of AMP-activated protein kinase
JPH06510280A (ja) タンパクキナーゼｃ阻害および新規化合物バラノール
Peana et al. Is catalase involved in the effects of systemic and pVTA administration of 4-methylpyrazole on ethanol self-administration?
Özmen et al. Effects of antiemetic drugs on glucose 6-phosphate dehydrogenase and some antioxidant enzymes
HK1109591A (en) Epoxide hydrolase complexes and methods therewith
US20010056119A1 (en) Materials and methods for the treatment of depression
Wells et al. Role of the serotonergic system in reduced pulmonary function after exposure to methamphetamine
Tawa et al. Impairment by Hypoxia or Hypoxia/Reoxygenation of Nitric Oxide–Mediated Relaxation in Isolated Monkey Coronary Artery: the Role of Intracellular Superoxide
Belvisi et al. Nitric oxide as a biological mediator

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091020

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100427